Friday, 21 August 2015

Life Cycle Management Strategies - Optimizing revenues and defending generic competition

Product Synopsis

GBI Research’s latest report, “Life Cycle Management Strategies Optimizing revenues and defending generic competition”” discusses various stages of product lifecycle management (LCM), Developmental, commercial and legal LCM strategies, objectives, benefits, factors impacting the choice of lifecycle management strategies, and keys to successful implementation of the strategies. The report provides detailed case studies for each of the key strategies such as indication expansion, reformulation, fixed-dose combinations, pricing strategies and so on.

Companies mentioned in the report are AbbVie, Actavis, AstraZeneca, Cipla, Gilead, GlaxoSmithKline, Gleevec, Janssen, MannKind, Merck, Novartis, Orexo, Otsuka, Pfizer, Roche, Salix Pharmaceuticals, Sanofi-Aventis, Solvay, Teva and Vifor Pharma.


Scope

Introduction of LCM and product life cycle

Objectives of LCM and factors impacting the choice of strategies

LCM strategies depending on the way of approach

Impact of LCM strategies on sales and growth trend of selected products

Patent term extension and market exclusivity in the US and Europe

LCM strategies of pipeline drugs of key players

Keys to successful implementation of LCM strategies

Download the Sample Copy Of this Report: http://www.researchmoz.us/enquiry.php?type=sample&repid=322850

Reasons to buy

Identify the key LCM strategies used by most of the pharmaceutical companies

Analyze the strategies to increase lifecycle and revenues of a drug

Gain an understanding on the implementation of multiple strategies for a single product by including case studies

Understand the operational pipeline strategies of key players


For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare, +1–518–621–2074
USA-Canada Toll Free: 866–997–4948

Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)